Yazar "Uyeturk, Ugur" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    The Antioxidant Effects of Sesamol on Bleomycin-Induced Oral Submucous Fibrosis
    (Istanbul University Press, 2022) Erimsah, Sevilay; Cetinkaya, Ayhan; Uyeturk, Ummugul; Uyeturk, Ugur; Yazir, Yusufhan
    Objective: Oral submucous fibrosis (OSF) is a disease characterized by abnormal collagen deposition that causes inflammation and malignancy in oral mucosal tissue. Fibroblasts and myofibroblasts, are the cells that show significant activation in the development of OSF. Bleomycin (BL) is a chemotherapeutic agent commonly used in cancer treatment that also causes inflammatory changes in the oral mucosa, initiating fibrosis in the oral submucosal tissue. Sesamol (SE) has antioxidative and anti-inflammatory properties which are abundant in sesame seeds and sesame oil, and SE has a beneficial effect on the mucosal layer. This experimental study aimed to investigate SE’s effects on BL-induced OSF. Materials and Methods: The study obtained 18 healthy adult male albino rats aged 3-4 months and weighing 200-250g from Bolu Abant Izzet Baysal University’s Experimental Animal Application and Research Center. The rats were divided randomly into control, BL, and BL + SE groups (n = 6 in each group). A model of OSF was established in the rats by administering 0.5 mg/mL of BL and 50 mg\kg of SE to the BL+SE group each day. The hematoxylin and eosin stain and Masson’s trichrome stain were used to assess histopathological changes in the oral mucosa. Results: The results revealed SE to have beneficial effects on BL-induced OSF through its antioxidant and anti-inflammatory properties. Histopathological evaluations and biochemical analysis of oral submucosal tissue samples also revealed SE to provide statistically significant protection against fibrosis in the oral mucosa (p < 0.01). Conclusion: This study has demonstrated oral submucous fibrosis that develops due to BL as well as SE to have an antioxidant effect on OSF regarding BL-induced reactive oxygen species (ROS) activation and collagen synthesis. © 2022, Istanbul University Press. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Genetic insights into bladder cancer: the impact of SIRT1 gene polymorphism
    (Taylor & Francis Inc, 2024) Bostanci, Emre; Kirkik, Duygu; Kalkanli Tas, Sevgi; Uyeturk, Ugur
    Bladder cancer (BC) has shown a significant global health concern with distinct pathological, genetic, and epigenetic characteristics. Its prevalence is influenced by various risk factors, including age, gender, and genetic predisposition. This study investigates the association between BC and the Sirtuin 1 (SIRT1) gene polymorphism rs369274325 in the Turkish population. Genomic DNA was isolated from peripheral blood samples and genotyping of rs369274325 polymorphism in SIRT 1 was investigated in 200 individuals (in 100 Turkish bladder cancer patients and 100 healthy individuals as the control group.) by real-time PCR. Demographic information, smoking and alcohol consumption status was analyzed by statistical analysis. Statistical analysis was performed by Pearson's Chi-square test. Smoking and alcohol consumption were significantly higher in BC patients compared to controls (p < 0.00018 and p < 0.0001, respectively). The genotypic distribution of SIRT1 rs369274325 did not show a significant difference between BC patients and controls (p = 0.5550). BC, influenced by genetic and environmental factors, has been linked to various gene mutations. SIRT1, involved in diverse physiological processes, is proposed to play a role in BC. However, our study did not find a significant association between SIRT1 rs369274325 polymorphism and BC in the Turkish population.
  • Küçük Resim Yok
    Öğe
    The role of phosphodiesterase type-5 inhibitors in Benign Prostatic Hyperplasia, current approaches
    (Galenos Yayincilik, 2013) Kemahli, Eray; Gucuk, Adnan; Uyeturk, Ugur
    Both benign prostatic hyperplasia (BPH) that manifested with lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are common health problems reducing quality of life in aging males. It has presumed that phosphodiesterase type 5 (PDE5) inhibitors which are primarily used in the treatment of ED may have therapeutic effects on BPH because of possible common pathophysiology between BPH and ED. There are many recent studies relevant to the this issue. Especially, after the FDA approval of tadalafil in the treatment of BPH, it has been entered to our daily practice as monotherapy or in combination with alpha-blocker drugs. PDE5 inhibitors may be preferred as a first line treatment option in patients who suffer both BPH and ED simultaneously, however, it is possible to use in patients with BPH only. Younger patients with low body mass index and with severe LUTS have more benefit with PDE5 inhibitor therapy. Flushing, gastroesophageal reflux, headache, and dyspepsia are the most frequently reported adverse effects of PDE5 inhibitors. These adverse effects are mild to moderate, and require the therapy to be discontinued in a small portion of patients. In this review, it is aimed to evaluate the use of PDE5 inhibitors in the treatment of BPH with the current literatures.